12月23日，水羊股份盘中下跌2.01%，截至13:58，报21.45元/股，成交2.10亿元，换手率2.70%，总市值 83.66亿元。 资金流向方面，主力资金净流出2662.74万元，特大单买入810.84万元，占比3.87%，卖出1518.57万元， 占比7.25%；大单买入4286.97万元，占比20.46%，卖出6241.99万元，占比29.79%。 分红方面，水羊股份A股上市后累计派现1.42亿元。近三年，累计派现7781.42万元。 机构持仓方面，截止2025年9月30日，水羊股份十大流通股东中，香港中央结算有限公司位居第六大流 通股东，持股818.33万股，相比上期增加565.94万股。华夏内需驱动混合A（011278）位居第八大流通 股东，持股162.08万股，为新进股东。财通资管消费升级一年持有期混合A（010715）位居第十大流通 股东，持股107.99万股，为新进股东。贝莱德中国新视野混合A（013426）退出十大流通股东之列。 责任编辑：小浪快报 今年以来水羊股份已经1次登上龙虎榜，最近一次登上龙虎榜为5月28日，当日龙虎榜净买入2448.89万 元；买入总计2.08亿元 ，占总成交 ...

截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 股884.16万股，相比上期减少9.23万股。香港中央结算有限公司位居第九大流通股东，持股726.71万 股，相比上期减少150.84万股。华夏中证1000ETF（159845）位居第十大流通股东，持股525.31万股， 为新进股东。 今年以来通化金马已经2次登上龙虎榜，最近一次登上龙虎榜为9月11日，当日龙虎榜净买入1.42亿元； 买入总计5.44亿元 ，占总成交额比29.22%；卖出总计4.02亿元 ，占总成交额比21.59%。 资料显示，通化金马药业集团股份有限公司位于吉 ...

潮宏基所属申万行业为：纺织服饰-饰品-钟表珠宝。所属概念板块包括：C2M概念、黄金股、年度强 势、医疗美容、基金重仓等。 潮宏基今年以来股价涨134.43%，近5个交易日涨1.83%，近20日涨4.32%，近60日跌14.61%。 今年以来潮宏基已经7次登上龙虎榜，最近一次登上龙虎榜为11月3日，当日龙虎榜净买入-9297.98万 元；买入总计4056.59万元 ，占总成交额比8.40%；卖出总计1.34亿元 ，占总成交额比27.66%。 资料显示，广东潮宏基实业股份有限公司位于广东省汕头市濠江区南滨路98号潮宏基广场总部办公写字 楼12-18层,香港湾仔皇后大道东248号大新金融中心40楼，成立日期1996年3月7日，上市日期2010年1月 28日，公司主营业务涉及 高档时尚珠宝首饰产品的设计、研发、生产及销售，女包业务。主营业务收 入构成为：时尚珠宝产品48.53%，传统黄金产品44.63%，代理品牌授权及加盟服务收入3.00%，皮具 2.99%，其他收入0.46%，其他产品0.40%。 分红方面，潮宏基A股上市后累计派现18.97亿元。近三年，累计派现8.00亿元。 12月22日，潮宏基盘中上涨2.07 ...

Company Overview - Guangdong Chao Hong Ji Industrial Co., Ltd. is located in Shantou, Guangdong Province, and was established on March 7, 1996. The company was listed on January 28, 2010. Its main business includes the design, research and development, production, and sales of high-end fashion jewelry products and handbags [2] - The revenue composition of the company is as follows: fashion jewelry products 48.53%, traditional gold products 44.63%, brand agency and franchise services 3.00%, leather goods 2.99%, other income 0.46%, and other products 0.40% [2] - The company belongs to the textile and apparel industry, specifically in the jewelry and watch sector, and is associated with concepts such as C2M, gold stocks, medical beauty, annual strong stocks, and cultivated diamonds [2] Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 6.237 billion yuan, representing a year-on-year growth of 28.35%. The net profit attributable to the parent company was 317 million yuan, with a year-on-year increase of 0.33% [2] - Since its A-share listing, the company has distributed a total of 1.897 billion yuan in dividends, with 800 million yuan distributed in the last three years [3] Stock Market Activity - On December 18, the company's stock price decreased by 2.05%, trading at 12.42 yuan per share, with a total transaction volume of 73.348 million yuan and a turnover rate of 0.67%. The total market capitalization is 11.035 billion yuan [1] - Year-to-date, the company's stock price has increased by 127.47%, with a decline of 2.89% over the last five trading days, a rise of 1.47% over the last 20 days, and a decrease of 15.22% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on November 3, where it recorded a net buy of -929.798 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders is 35,300, a decrease of 12.70% from the previous period. The average circulating shares per person increased by 14.54% to 24,565 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 64.5361 million shares, a decrease of 877,600 shares from the previous period. New shareholders include Hai Fu Tong Consumer Preferred Mixed A and Gold Stock ETF [3]

Group 1: Company Updates - Several companies, including 美之选 (MEDG), Ga Sai Tong (GST), 青民数科 (QMSK), 星妍 (AGIE), and 中毅资本, have updated their prospectuses to advance their respective U.S. IPO processes [1][3][5][7][9] - 美之选 plans to issue 3.33 million shares at a price range of $4 to $5 per share, aiming to raise between $13.33 million and $16.67 million [1][3] - Ga Sai Tong intends to issue 1.3 million shares at a price range of $5 to $7 per share, with a fundraising target of $6.5 million to $9.1 million [1][5] - 青民数科 plans to issue 6.25 million shares at a price range of $4 to $6 per share, targeting $25 million to $37.5 million in fundraising [1][7] - 星妍 aims to issue 1.5 million shares at a price range of $4 to $6 per share, with a fundraising goal of $6 million to $9 million [1][8] Group 2: Financial Performance - 美之选 reported revenue of $3.25 million and a net profit of $0.98 million for the six months ending December 31, 2024 [3] - Ga Sai Tong generated revenue of $1.36 million and a net profit of $0.25 million for the first half of 2025 [5] - 青民数科 reported revenue of $52.86 million and a net profit of $2.25 million for the twelve months ending March 31, 2025 [7] - 星妍 achieved revenue of $4.51 million and a net profit of $0.49 million for the six months ending June 30, 2025 [8] - 中毅资本 reported revenue of $0.654 million but incurred a net loss of $0.189 million for the twelve months ending March 31, 2025 [9] Group 3: Market Overview - The global medical aesthetic services market was valued at $15.304 billion in 2023 and is projected to grow at a CAGR of 11% from 2023 to 2028, with non-surgical procedures expected to outpace surgical ones [25] - The beauty and personal care market in Hong Kong is projected to grow at a CAGR of 1.9% from 2024 to 2028, while the skincare segment is expected to grow at a CAGR of 1.81% during the same period [25]

Investment Rating - The report rates the Chinese medical beauty industry as a "Buy" due to its significant growth potential and increasing consumer demand [17]. Core Insights - The medical beauty industry in China is rapidly evolving, driven by technological advancements, changing consumer preferences, and supportive government policies [12][17]. - The market is expected to exceed 200 billion RMB by 2027, indicating robust growth opportunities [17]. Industry Overview - The medical beauty industry encompasses a wide range of services, including invasive and non-invasive procedures, with a focus on safety and professionalism [4][7]. - The consumer base is diversifying, now including men, the elderly, and teenagers, reflecting a broader demand for beauty and health [5]. Market Size and Growth Trends - As of 2024, the market size has surpassed 100 billion RMB, making China the second-largest medical beauty market globally [17]. - The growth is fueled by rising disposable incomes and a shift in consumer attitudes towards personal appearance and health [17][21]. Market Drivers - Changing consumer demands are leading to a preference for minimally invasive procedures and personalized beauty solutions [23][24]. - Technological innovations, such as AI and digital platforms, are enhancing service delivery and consumer engagement [25][66]. Consumer Behavior and Demand Analysis - The primary consumer demographic consists of women aged 20 to 40, with increasing participation from men and older adults [28][29]. - High-income consumers are driving demand for premium, customized services, while middle-income consumers seek value for money [30][41]. Competitive Landscape - The market is characterized by a concentration of large chain medical beauty groups that leverage capital and technology to maintain competitive advantages [50][57]. - Emerging innovative companies are focusing on niche markets and utilizing advanced technologies to differentiate their offerings [52]. Technological Development Trends - Key advancements in injection techniques and laser technologies are improving treatment safety and effectiveness [62][64]. - AI-assisted diagnostics and treatment planning are becoming integral to enhancing patient outcomes and satisfaction [66][67].

| | | 2025年1-6月前五名客户 | | | --- | --- | --- | --- | | 序号 | 客户名称 | 销售金额 | 占营业收入比重 | | 1 | 客户 A | 3,374.35 | 18.72% | | 2 | 中国科学院 | 1,579.50 | 8.76% | | 3 | 客户 B | 685.92 | 3.80% | | 4 | 昂坤视觉 | 557.52 | 3.09% | | 5 | 复旦大学 | 555.58 | 3.08% | | | 合计 | 6,752.87 | 37.46% | 瑞财经 严明会 12月8日，上海频准激光科技股份有限公司（以下简称：频准激光）科创板IPO获受理， 保荐机构中信建投证券，保荐代表人周云帆、仇浩瀚，会计师事务所为中汇会计师事务所。 频准激光成立于2017年，注册资本3000万元，主营高端光纤激光器的研发与生产，主要瞄准量子信息、 激光雷达、先进工业和医疗美容等市场。 公司本次拟募资14.1亿元，用于精准激光系统产业化建设项目、研发中心建设项目、全同芯光武汉研发 中心建设项目，以及补充流动资金。 截至招股说明书签署日，频准激光董事长、总 ...

证券日报网讯12月1日，融捷健康（300247）在互动平台回答投资者提问时表示，本次秋季广交会公司 展出的部分远红外理疗房具备光疗功能，可用于医疗美容领域。 ...

Group 1 - The company confirmed that some of the far-infrared therapy products exhibited at the Autumn Canton Fair have phototherapy functions and can be used in the medical beauty field [2]

Core Viewpoint - Changguang Huaxin's stock price has shown significant growth this year, with a year-to-date increase of 201.36%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Changguang Huaxin achieved a revenue of 339 million yuan, representing a year-on-year growth of 67.42% [2]. - The net profit attributable to the parent company for the same period was 20.94 million yuan, reflecting a substantial increase of 133.04% year-on-year [2]. Stock Market Activity - As of November 28, the stock price of Changguang Huaxin was 117.50 yuan per share, with a trading volume of 460 million yuan and a turnover rate of 2.26% [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on November 26, where it recorded a net purchase of 129 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Changguang Huaxin was 18,200, an increase of 25.49% from the previous period [2]. - The average number of circulating shares per shareholder was 5,835, which decreased by 20.31% compared to the previous period [2]. Business Overview - Changguang Huaxin, established on March 6, 2012, specializes in the research, manufacturing, and sales of semiconductor laser chips and related components [2]. - The main revenue sources include high-power single-tube series (76.98%), VCSEL and optical communication chips (11.47%), and other products [2].